Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „dapagliflozin“
Suchtreffer
Begriffe & Kennungen
Forxiga · 4.5 · Dapagliflozin may increase renal lithium excretion and the blood lithium levels may be decreased. Serum concen
Eintrag öffnenForxiga · 4.5 · Diuretics Dapagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the ris
Eintrag öffnenForxiga · 4.5 · Effect of dapagliflozin on other medicinal products
Eintrag öffnenForxiga · 4.5 · Effect of other medicinal products on dapagliflozin
Eintrag öffnenForxiga · 4.5 · Following coadministration of dapagliflozin with mefenamic acid (an inhibitor of UGT1A9), a 55% increase in da
Eintrag öffnenForxiga · 4.5 · Following coadministration of dapagliflozin with rifampicin (an inducer of various active transporters and dru
Eintrag öffnenForxiga · 4.5 · In in vitro studies, dapagliflozin neither inhibited cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9
Eintrag öffnenForxiga · 4.5 · In interaction studies conducted in healthy subjects, using mainly a single-dose design, dapagliflozin did not
Eintrag öffnenForxiga · 4.5 · The metabolism of dapagliflozin is primarily via glucuronide conjugation mediated by UDP glucuronosyltransfera
Eintrag öffnenForxiga · 4.8 · Chronic kidney disease In the dapagliflozin renal outcome study in patients with chronic kidney disease (DAPA-
Eintrag öffnenForxiga · 4.8 · For studies of dapagliflozin in monotherapy, as add-on to metformin or as add-on to sitagliptin (with or witho
Eintrag öffnenForxiga · 4.8 · Heart failure In the dapagliflozin cardiovascular outcome study in patients with heart failure with reduced ej
Eintrag öffnenForxiga · 4.8 · In the DAPA-CKD study, eGFR decreased over time in both the dapagliflozin group and the placebo group. The ini
Eintrag öffnenForxiga · 4.8 · In the DAPA-CKD study, events of DKA were not reported in any patient in the dapagliflozin group and in 2 pati
Eintrag öffnenForxiga · 4.8 · In the DAPA-CKD study, major events of hypoglycaemia were reported in 14 (0.7%) patients in the dapagliflozin
Eintrag öffnenForxiga · 4.8 · In the DAPA-HF and DELIVER studies, eGFR decreased over time in both the dapagliflozin group and the placebo g
Eintrag öffnenForxiga · 4.8 · In the DAPA-HF study, no patient reported serious adverse events of genital infections in the dapagliflozin gr
Eintrag öffnenForxiga · 4.8 · In the DECLARE study, no increased risk of major hypoglycaemia was observed with dapagliflozin therapy compare
Eintrag öffnenForxiga · 4.8 · In the dapagliflozin cardiovascular outcomes study in type 2 diabetes mellitus (DECLARE study, see section 5.1
Eintrag öffnenForxiga · 4.8 · The dapagliflozin safety profile observed in a clinical study in children aged 10 years and above with type 2
Eintrag öffnen